Skip to main navigation Skip to search Skip to main content

Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review

  • Erasmus Centre for Health Economics Rotterdam (EsCHER)
  • Austrian National Public Health Institute
  • London School of Economics
  • International Association of Mutual Benefit Societies, Brussels
  • Erasmus School of Health Policy and Management (ESHPM)
  • Myeloma Patients Europe (MPE), 1050 Brussels, Belgium
  • OptiMedis AG (Germany)
  • Witten/Herdecke University
  • Assistance publique – Hôpitaux de Paris
  • Université Paris-Est Créteil
  • Institute for Medical Technology Assessment (iMTA)

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
17 Downloads (Pure)

Abstract

Background:

Policymakers face challenges in developing pricing policies for potentially innovative healthcare technologies (pIHTs) that balance limited budgets, access, and incentives for innovation. This study aimed to map existing evidence and identify knowledge gaps regarding price determinants and pricing policies for pIHTs and their effect on access and sustainability.

Methods:

We conducted a scoping Review of scientific and grey literature in English published between 2014 and September 2023 with pre-specified inclusion and exclusion criteria to identify stakeholder-informed price determinants, pricing policies applied by European Economic Area (EEA) or Organisation for Economic Cooperation and Development (OECD) member states, and their access-related impacts. Literature databases and various stakeholder organisation websites were searched. Further records were included through snowballing and manual addition.

Results:

135 Records were included. Stakeholder views on price determinants were available from 15 records and predominantly involved value-based determinants. Pricing policies in EEA/OECD member states are heterogeneous and often feature a mix of policy interventions and implementation methods. External price referencing (EPR), while yielding short-term affordability improvements, is associated with price inequities and launch strategies impairing patient access. Policies combining pricing methods and considering a pIHT’s value have more positive access-related impact but may face feasibility and implementation challenges. Two records mentioned medical device pricing; none featured environmental aspects.

Conclusion:

While EPR is commonly applied across Europe, value-informed pricing in connection with health technology assessment is more favoured regarding pIHT access in the literature. Knowledge gaps concern medical device pricing, stakeholder views on price determinants, and the implementation of environmental aspects in pIHT pricing.
Original languageEnglish
Pages (from-to)479-508
Number of pages30
JournalEuropean Journal of Health Economics
Volume27
Issue number2
DOIs
Publication statusPublished - Mar 2026

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review'. Together they form a unique fingerprint.

Cite this